A 52-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Ustekinumab in Patients With Moderate-to-Severe Plaque Psoriasis
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 07 Dec 2017
At a glance
- Drugs Ixekizumab (Primary) ; Ustekinumab
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms IXORA-S
- Sponsors Eli Lilly
- 07 Dec 2017 This trial was completed in Belgium (end date: 2017-10-05), according to European Clinical Trials Database record.
- 24 Nov 2017 This trial was completed in Germany (end date: 2017-10-05), according to European Clinical Trials Database.
- 15 Nov 2017 This trial has been completed in Sweden (End date:2017-10-05) as per European Clinical Trials Database record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History